Inventor · disambiguated record
Xiaozhang Zheng
Also filed as: ZHENG XIAOZHANG
106 granted patents·53 pending applications·1,234 citations·filing 2001–2025
99Inventor score
Files withFORMA THERAPEUTICS INC46KYMERA THERAPEUTICS INC37VALO HEALTH INC22NEUROGEN CORP18BAIR KENNETH W9
Top patents by PatentIndex Score
159 records- 0199US10829461B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 10, 2020·15 cites·12 claims
- 0299US10829462B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 10, 2020·15 cites·17 claims
- 0399US10377726B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·22 cites·10 claims
- 0499US10112915B23-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Oct 30, 2018·41 cites·31 claims
- 0598US11279681B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Mar 22, 2022·6 cites·20 claims
- 0698US11117889B1IRAK degraders and uses thereofKYMERA THERAPEUTICS INC·Filed 2020·Granted Sep 14, 2021·28 cites·28 claims
- 0798US10822316B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 3, 2020·10 cites·15 claims
- 0898US10494354B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·17 cites·17 claims
- 0998US10494353B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·17 cites·12 claims
- 1098US10472371B2Compositions for activating pyruvate kinaseFORMA THERAPEUTICS INC·Filed 2019·Granted Nov 12, 2019·13 cites·3 claims
- 1198US10472337B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 12, 2019·17 cites·12 claims
- 1298US10428031B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 1, 2019·15 cites·20 claims
- 1398US10421731B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 24, 2019·15 cites·19 claims
- 1498US10421732B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 24, 2019·16 cites·13 claims
- 1598US10414738B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·16 cites·20 claims
- 1698US10239845B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Mar 26, 2019·25 cites·42 claims
- 1798US10214501B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Feb 26, 2019·20 cites·38 claims
- 1898US10214500B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Feb 26, 2019·20 cites·35 claims
- 1998US10208052B1Compositions for activating pyruvate kinaseFORMA THERAPEUTICS INC·Filed 2018·Granted Feb 19, 2019·36 cites·10 claims
- 2098US9630922B23-spiro-7-hydroxamic acid tetralins as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Apr 25, 2017·49 cites·33 claims
- 2197US12258341B2IRAK degraders and uses thereofKYMERA THERAPEUTICS INC·Filed 2023·Granted Mar 25, 2025·5 cites·18 claims
- 2297US11980611B2Treating sickle cell disease with a pyruvate kinase R activating compoundNOVO NORDISK HEALTHCARE AG·Filed 2022·Granted May 14, 2024·3 cites·4 claims
- 2397US11807636B2IRAK degraders and uses thereofKYMERA THERAPEUTICS INC·Filed 2022·Granted Nov 7, 2023·6 cites·19 claims
- 2497US11702412B2Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Jul 18, 2023·4 cites·18 claims
- 2597US11649242B2Pyrrolopyrrole compositions as pyruvate kinase (PKR) activatorsFORMA THERAPEUTICS INC·Filed 2021·Granted May 16, 2023·5 cites·4 claims
- 2697US11396513B2Compositions for activating pyruvate kinaseFORMA THERAPEUTICS INC·Filed 2020·Granted Jul 26, 2022·6 cites·8 claims
- 2797US10988450B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Apr 27, 2021·6 cites·14 claims
- 2897US10513501B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 24, 2019·11 cites·20 claims
- 2997US10494352B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·12 cites·20 claims
- 3097US10494351B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·12 cites·20 claims
- 3197US10464910B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2019·12 cites·15 claims
- 3297US10464909B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2019·12 cites·17 claims
- 3397US10457652B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 29, 2019·12 cites·18 claims
- 3497US10450283B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 22, 2019·14 cites·16 claims
- 3597US10450284B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 22, 2019·14 cites·13 claims
- 3697US10442776B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 15, 2019·15 cites·18 claims
- 3797US10183934B2Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Jan 22, 2019·27 cites·28 claims
- 3897US9637453B23-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted May 2, 2017·51 cites·31 claims
- 3996US12213969B22-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitorsVALO HEALTH INC·Filed 2023·Granted Feb 4, 2025·2 cites·20 claims
- 4096US11730721B22-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Aug 22, 2023·3 cites·20 claims
- 4196US11591332B2IRAK degraders and uses thereofKYMERA THERAPEUTICS INC·Filed 2020·Granted Feb 28, 2023·9 cites·19 claims
- 4296US11352350B2IRAK degraders and uses thereofKYMERA THERAPEUTICS INC·Filed 2019·Granted Jun 7, 2022·20 cites·11 claims
- 4396US11299484B2Inhibiting fatty acid synthase (FASN)FORMA THERAPEUTICS INC·Filed 2020·Granted Apr 12, 2022·3 cites·22 claims
- 4496US11014927B2Pyrrolopyrrole compositions as pyruvate kinase (PKR) activatorsFORMA THERAPEUTICS INC·Filed 2018·Granted May 25, 2021·6 cites·3 claims
- 4596US10836771B2Compositions for activating pyruvate kinaseFORMA THERAPEUTICS INC·Filed 2019·Granted Nov 17, 2020·7 cites·2 claims
- 4696US10407418B2Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 10, 2019·16 cites·19 claims
- 4796US6566367B2Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidinesPFIZER·Filed 2001·Granted May 20, 2003·124 cites·23 claims
- 4895US12091411B2IRAK degraders and uses thereofKYMERA THERAPEUTICS INC·Filed 2023·Granted Sep 17, 2024·5 cites·9 claims
- 4995US10772874B2Compounds and compositions for the inhibition of NAMPTFORMA TM LLC·Filed 2019·Granted Sep 15, 2020·6 cites·11 claims
- 5094US12150995B2IRAK degraders and uses thereofKYMERA THERAPEUTICS INC·Filed 2021·Granted Nov 26, 2024·4 cites·15 claims
Showing the top 50 of 159 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Xiaozhang Zheng files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →